Galactitol, Quantitative, Urine
Monitoring dietary therapy of patients with galactosemia
Genetics Test Information Provides information that may help with selection of the correct test or proper submission of the test request
Dietary monitoring of patients with an established diagnosis of galactosemia.
Clinical Information Discusses physiology, pathophysiology, and general clinical aspects, as they relate to a laboratory test
Galactosemia is an autosomal recessive disorder that results from a deficiency of 1 of the 3 enzymes catalyzing the conversion of galactose to glucose: galactose-1-phosphate uridyltransferase (GALT, #230400), galactokinase (GALK, #230200), and uridine diphosphate galactose-4-epimerase (GALE, #230350).(1) GALT deficiency is the most common cause of galactosemia and is often referred to as classic galactosemia. The complete or near complete deficiency of the GALT enzyme is life threatening. If left untreated, complications include liver failure, sepsis, cognitive and intellectual disabilities, and death. Galactosemia is treated with a galactose-free diet, which allows for rapid recovery from the acute symptoms and a generally good prognosis. Despite adequate treatment from an early age, children with galactosemia remain at increased risk for developmental delays, speech problems, and abnormalities of motor function. Females with galactosemia are at increased risk for premature ovarian failure. Based upon reports by newborn screening programs, the frequency of classic galactosemia in the United States is approximately 1 in 30,000.
Galactose levels may be continuously elevated in individuals affected with galactosemia even with a galactose-restricted diet regimen due to an endogenous production of galactose. The reduction of galactose to galactitol is an alternate pathway of galactose disposition when galactose metabolism is impaired. The excretion of abnormal quantities of galactitol in the urine of patients is characteristic of this disorder and suggests ineffective dietary restriction or compliance in patients with galactosemia. Monitoring the excretion of galactitol in the urine of patients with galactosemia is an important marker of adequate treatment.
Reference Values Describes reference intervals and additional information for interpretation of test results. May include intervals based on age and sex when appropriate. Intervals are Mayo-derived, unless otherwise designated. If an interpretive report is provided, the reference value field will state this.
0-11 months: <109 mmol/mol creatinine
1-3 years: <52 mmol/mol creatinine
4–17 years: <16 mmol/mol creatinine
> or =18 years: <13 mmol/mol creatinine
The concentration of galactitol is provided along with reference ranges for patients with galactosemia and normal controls.
Clinical Reference Provides recommendations for further in-depth reading of a clinical nature
1. Online Mendelian Inheritance in Man. 230400, 230200, and 230350, respectively. National Center for Biotechnology Information. Available at www.ncbi.nlm.nih.gov/Omim
2. Elsas LJ: Galactosemia. NCBI GeneReviews. Updated 2010, Oct 26. Available from www.ncbi.nlm.nih.gov/books/NBK1518
3. Holton JB, Walter JH, Tyfield LA: Galactosemia. In The Metabolic and Molecular Basis of Inherited Disease. Vol 1. Eighth edition. Edited by CR Scriver, AL Beadut. New York, McGraw-Hill Book Company, 2001, pp 1553-1587